Neuralink to Test Vision Device in Humans Next Year

The interface aims to restore sight for those who cannot use standard retinal solutions by stimulating the visual cortex.

Updated on Oct. 24, 2026 in Stroke

A detailed macro view of a glowing, intricate micro-electrode array floating in a dark, clinical laboratory space. — Neuralink aims to begin human trials for its Blindsight device next year, offering a potential pathway to restore vision by directly stimulating the visual cortex. AI Illustration. Upload story photo >

Live Poll

Is now the right time to begin human trials for experimental sight-restoring brain implants?

Neuralink plans to begin human implantation of its Blindsight vision device within 6 to 12 months. The technology, which received FDA Breakthrough Device Designation in September 2024, aims to restore visual perception for individuals who cannot use traditional retinal or optic-nerve solutions.

Why it matters

This development represents a potential new pathway for those with profound vision loss who currently lack treatment options. By bypassing damaged optical pathways, the interface seeks to restore sight directly through the brain.

The Blindsight device received FDA Breakthrough Device Designation in 2024 following long-term testing in a monkey subject that lasted three years. While the company has implemented N1 motor-control devices in 21 participants, human clinical results for the Blindsight interface remain pending.

The players

Neuralink

A neurotechnology company developing implantable brain-computer interfaces to restore motor control and vision.

The details

The Blindsight interface functions by stimulating the visual cortex directly to create visual perception. The system acts as a write-function that sends information into the brain to generate images. Developers project that initial visual resolution provided by the device will resemble early Atari or Nintendo graphics.

September 17, 2024: The FDA granted the device Breakthrough Device Designation.
Mid-2025: A monkey subject completed three years of long-term implant testing.
January 28, 2026: 21 participants received the separate N1 motor-control implant.
August 4, 2026: The company announced plans for human implants within 6 to 12 months.
October 2026: Reporting confirmed the current timeline for the device.

Health Landscape

This development marks an expansion of brain-computer interface applications beyond motor restoration. It follows the precedent set by the N1 motor-control implant, signaling a broader effort to address sensory impairment by interfacing directly with the brain.

This experimental technology is specifically intended for individuals who are not candidates for standard retinal or optic-nerve solutions. Anyone interested in emerging visual prosthetics should discuss the status of clinical trials and eligibility with their physician.

The takeaway

Neuralink expects to begin human trials for its visual brain implant in the coming months. Those living with vision loss should follow clinical trial registries to track the progress of this technology and speak with their doctor about current options for vision restoration.